– USA, MA – Omega Therapeutics, Inc. (Nasdaq: OMGA), a clinical-stage biotechnology company, today announced the appointment of Rainer Boehm to its Board as an independent director, bringing over 30 years of clinical and managerial experience to the Board.
“Rainer’s growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase of the Company’s trajectory. I look forward to working closely with him as Omega continues to advance its clinical pipeline and demonstrate the broad capabilities of its pioneering drug development platform,” said Co-founder and Board Chairman, Dr. Noubar Afeyan.
Mahesh Karande, CEO, added, “We are thrilled to welcome Rainer to our Board and look forward to leveraging his significant drug development expertise, strategic thought-leadership, and executive management skills as we work to advance our new class of programmable epigenetic medicines. Rainer is a recognized industry leader with a strong track record of working with and growing innovative clinical-stage companies and has extensive experience managing global drug development and commercialization.”
Rainer Boehm will also join the audit and compensation committees.
About Rainer Boehm
Rainer Boehm held several senior management positions during his extensive tenure at Novartis Pharma AG and its predecessor, CIBA-Geigy, spanning from 1988 to 2017, most recently as Chief Commercial & Medical Affairs Officer. He was a key figure in the successful establishment of Novartis Oncology. He oversaw the launch and life cycle management of many blockbuster brands in different geographies globally, amongst them Femara, Zometa, and Glivec in oncology, as well as Cosentyx and Entresto and the immunology and cardiovascular disease areas. Before joining Novartis, he served as unit head at the Psychiatric Hospital in Zwiefalten, Germany. Mr. Boehm serves on the boards of Cellectis SA (Nasdaq: CLLS), Humanigen Inc. (Nasdaq: HGEN), BioCopy, AG (private), and Berlin Cures, AG (private).
“Omega is pioneering a new class of programmable mRNA therapeutics that have the potential to transform the way we approach difficult-to-treat diseases,” said Mr. Boehm. “This is an exciting time for the Company, and I look forward to partnering with this accomplished board of directors and management team and sharing insights as they continue to pave new roads through the discovery and development of epigenomic controllers for patients in need.”
He holds a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University, Strasbourg Campus in France. Recently, he commenced a Master of Public Health program at the Universities of Basel / Bern / Zurich in Switzerland.
Omega Therapeutics was founded by Flagship Pioneering, a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company’s OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism’s life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega’s process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s modular and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips™, from amongst thousands of unique, mapped, and validated genome-wide DNA sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
